AzTrials
AzTrials

AgingMemoAgeNCT06501495

Links Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG

A study testing video polysomnography and Attention task in people with Aging and Alzheimer Disease, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

With age, memory processes (encoding, consolidation and retrieval) as well as daytime vigilance are altered. Sleep is also impaired in older adults, notably slow waves that are known to play a key role in memory consolidation. Read more about this study

Who is it for?
Ages 18 to 85 yearsHealthy volunteers can take part
Conditions the study is for
Aging, Alzheimer Disease
What is being tested?
video polysomnography and Attention task
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
1 siteFrance
Study dates
24 Apr 2025to Apr 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult
  • Common Inclusion Criteria for All Three Groups:

Male or female Signed informed consent Affiliated with a social security system Native French speakers Completed at least 7 years of schooling (minimum 9th grade level)

Specific Inclusion Criteria for Each Group:

Patients:

Age: 60 to 85 years Prodromal stage of Alzheimer's disease diagnosed according to international diagnostic criteria, characterized by a clinical phenotype of progressive amnesic syndrome of the hippocampal type, associated with biological markers of Alzheimer's disease 1) from lumbar puncture (Aβ < 600 pg/mL and ptau > 60 pg/mL)or 2) amyloid PET (positron emission tomography), or 3) with positive plasma Alzheimer's biomarkers

Cognitively Healthy Seniors:

Age: 60 to 85 years Age and sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the MMSE (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test

Young Adults:

Age: 18 to 35 years Sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the MMSE (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • Maladies du Sommeil

    Paris, 75013

    Isabelle Arnulf, Pr, 01 42 16 77 03 ext. +33, isabelle.arnulf@aphp.fr

    Thomas Andrillon, PhD, 01 42 16 77 02 ext. +33, thomas.andrillon@icm-institute.org

    Recruiting

Other trials in France

About this study

Official title: Slow Waves During Sleep and Wakefulness: a Common Denominator for Cognitive and Attentional Disorders in Normal and Pathological Aging (Exploratory Study)

With age, memory processes (encoding, consolidation and retrieval) as well as daytime vigilance are altered. Sleep is also impaired in older adults, notably slow waves that are known to play a key role in memory consolidation. Interestingly, some slow waves can also be detected in EEG recordings during wakefulness, and have been related to vigilance fluctuations.

The investigators believe that slow waves, during both sleep and wakefulness, could constitute a common biomarker of sleep disturbances and daytime vigilance problems. A dysregulation of slow waves could thus explain the impact of aging on the different memory processes. Since alterations in memory capacity, attention, and sleep quality are further exacerbated in patients with Alzheimer's disease (AD), the investigators propose to study the links between aging (normal and pathological), sleep and daytime vigilance alterations, and their impacts on the different key stages of memory.

Read more

The investigators will examine the associations between slow waves and changes in memory and vigilance in normal and pathological aging by studying young adults, seniors without cognitive disorders, and patients with prodromal AD. By replaying sensory cues associated with learning material during sleep, the investigators will also evaluate the effectiveness of auditory stimulation during sleep to enhance memory consolidation in older adults without and without cognitive deficits.

Overall, this study aims to better understand the relationships between slow waves, aging, memory, and vigilance, providing insights into cognitive decline and potential interventions in aging and Alzheimer's disease.

Read the detailed description

Introduction Aging is accompanied by cognitive decline, particularly affecting memory functions. Additionally, both the quantity and quality of sleep decrease with advancing age, specifically altering sleep oscillations (such as slow waves) that are involved in the reactivation of memories and are thus central to memory consolidation.

Aging is also associated with difficulties in maintaining daytime vigilance, even after a period of rest, impacting cognitive function, including the encoding and retrieval of memories. Interestingly, recent studies have revealed the existence of sleep intrusions, in the form of slow waves, in wakefulness EEG recordings. These have been associated with subjective and objective markers of fatigue, predict transient lapses in attention, and are particularly present after sleep deprivation. the investigators believe that slow waves, during both sleep and wakefulness, could constitute a common biomarker of sleep disturbances and daytime vigilance problems. A dysregulation of slow waves (fewer during sleep, more during wakefulness) could thus explain the impact of aging on the three fundamental stages of the memory process (encoding, consolidation, and retrieval). Since alterations in memory capacity, attention, and sleep quality are further exacerbated in patients with Alzheimer's disease (AD), the investigators propose to study the links between aging (normal and pathological), sleep and daytime vigilance alterations, and their impacts on the different key stages of memory.

Aims Our main objective is to test the associations between slow waves (during sleep and wakefulness) and the alterations in memory and vigilance during normal and pathological aging by studying young adults, seniors without cognitive disorders, and patients of the same age with prodromal AD.

Additionally, the investigators aim to test the efficiency of targeted memory reactivation (TMR) in older adults with and without cognitive deficits. TMR is a technique that has been showed to boost memory consolidation in young adults and mice by replaying during sleep sensory cues that have been previously associated with the learning material.

Methods Participants To do so, the stydy will include three groups: young adults (18-35 y.o), older adults without cognitive deficits (65-80 y.o), and older adults of the same age and with cognitive deficits (patients with prodromal Alzheimer's disease). Prodromal stage of Alzheimer's disease diagnosis will be performed by trained neurologists at the at the Memory and Alzheimer's Disease Institute (IM2A) of the Pitié-Salpêtrière Hospital, according to international diagnostic criteria as a clinical phenotype of progressive amnestic syndrome of the hippocampal type, associated with biological markers of Alzheimer's disease from lumbar puncture (Aβ < 600 pg/mL and ptau > 60 pg/mL). During their clinical follow-up at the IM2A, patients diagnosed with prodromal AD will be offered the opportunity to participate in the study, in agreement with their attending physician. Healthy volunteers (both young and elderly) will be recruited through public announcements via the Relay for Information on Cognitive Sciences (RISC), from patients' relatives, or through the Fondation Recherche Alzheimer. Participation of both patients and healthy individuals will be voluntary, free, and informed. Participants will be contacted (by phone or email) by one of the study investigators. They will be informed about the conduct and purpose of the research protocol.

Protocol All participants will spend 3 days in the Sleep Disorders Unit of the Salpêtrière Hospital, including two nights.

Day 1: Participants will arrive in the late afternoon and will be fitted with the sensors required for video-polysomnography to monitor vigilance and sleep stages throughout the experiment. Then, they will 1) complete an attention task (modified version of the Sustained Attention to Response Task, SART), 2) perform an associated memory task (old/new task) consisting on recognition of words they have seen in the SART task, and 3) their resting-state EEG activity will be recorded. They will sleep in the laboratory (night 1, without intervention).

Day 2: Participants will retake the word recognition task the morning after night 1. During the afternoon they will fill different sleep questionnaires to assess their subjective feeling about their sleep: Pittsburgh sleep quality index (PSQI), Epworth sleepiness scale and the REM Behavior Disorder Screening Questionnaire (RBDSQ), as well as the geriatric depression scale (GDS). In the late afternoon, they will perform the learning and test phases of the visuospatial memory task. They will then sleep in the laboratory (night 2, with TMR). During their slow-wave sleep, half of the sounds associated with the items from the visuospatial memory task will be replayed.

Day 3: Participants will once again perform the visuospatial memory test the morning after night 2.

Being tested
video polysomnography, Attention task
Keywords
aging, Alzheimer's disease, sleep, memory, attention, slow
Medical subject headings
Alzheimer Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • video polysomnographyOther

    video polysomnography during 2 nights

  • Attention taskOther

    Attention task : SART Test (Sustained Attention to Response Task)

Study groups in NCT06501495
Study groupRoleWhat they receive
young adults, older adults without cognitive deficits, prodromal Alzheimer's DiseaseExperimentalyoung adults, older adults without cognitive deficits, prodromal Alzheimer's Disease
Receives: Other: video polysomnography; Other: Attention task

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. slow waves density

    quantifying slow waves with their density (during sleep, wakefulness at rest and during tasks)

    Measured: 2 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jul 2024
  2. Study start24 Apr 2025
  3. Primary completionApr 2027 (estimated)
  4. Study completionApr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06501495
Sponsor's protocol ID
APHP240231
Acronym
MemoAge
Status last verified
Apr 2026
First submitted
1 Jul 2024
Last updated
13 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing video polysomnography and Attention task in people with Aging and Alzheimer Disease, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Marc Teichmann, MD (01 42 16 75 34, marc.teichmann@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

slow waves density (time frame: 2 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in